• Register

Hikma sees 23% growth in full-2013 revenue

: Monday, February 17 - 2014 @ 00:53

Jordan’s Hikma Pharmaceuticals has said its full-year revenue is expected to grow 23%, up from its prior forecast of about 20%, thanks to a strong performance in its injectables and generics businesses towards the end of 2013, Reuters has reported. The London-listed company also raised its full-year generics revenue forecast to $270m, as sales of the antibiotic continued to rise. Hikma has already raised its 2013 revenue forecast three times and said in November that it expected revenue from its generics unit to be about $260m.

Today's Top Stories

Posted by

Monday, February 17- 2014 @ 0:53 UAE local time (GMT+4) Replication or redistribution in whole or in part is expressly prohibited without the prior written consent of Mediaquest FZ LLC.

AME Info Services

Business DirectoryVIEW ALL

Search by name

Search by industry

Browse alphabetically


Search for jobs

Latest Jobs